Ginofort is an antimycotic drug for topical administration. The active substance of the drug belongs to the group of imidazole derivatives and has a pronounced fungicidal activity, that is, it is capable of changing the lipid composition of the cell membranes of fungi of the genus Candida, Trichophyton, Micosporum, Epidermaphyton, which are sensitive to it, by inhibiting the formation of lanostrel in ergosterol. At the same time, under the influence of the drug, the permeability of the cell membranes of fungi changes, osmotic equilibrium decreases, vital processes in the cell are disturbed, and the cell dies.
Release form and composition
Ginofort is produced in the form of a vaginal cream, which is a uniform, soft, without visible stratification and free from foreign particles of a substance of white or almost white color.
One gram of Ginofort cream contains 20 mg of butoconazole nitrate and a number of auxiliary components: mineral oil, sorbitol, glycerol monostearate, polyglycerol-3-oleate, colloidal silicon dioxide, wax, disodium edetate, methyl and propyl parahydroxybenzoate, propylene glycol, water.
Pharmacies cream comes packaged in 5 grams in polypropylene applicators. Each applicator is packed in a polystyrene box and a laminated bag. One carton contains one pencil case with an applicator and instructions for using the preparation.
Indications for use
In accordance with the instructions to Ginofort, the drug is intended for the treatment of fungal inflammatory diseases of the vagina. In particular, the cream is prescribed for infections that are caused by fungi of the genus Candida albicans.
The instructions to Ginofort indicate that the drug should not be prescribed if the patient has an individual intolerance to butoconazole or any of the auxiliary components that are part of the cream.
Also, the use of Ginofort is contraindicated in pediatrics, since the applicator may cause injury. The possibility of using the cream for the treatment of patients under 18 years of age can only be determined by the attending physician.
According to the information specified in the instructions for the preparation, the drug does not affect the ability to conceive and does not possess teratogenic and mutagenic properties. However, during pregnancy, the cream can be prescribed solely by decision of the attending physician and after a thorough assessment of the potential benefits for the future mother and the possible risks to the fetus. It should be remembered that careless handling of the applicator can cause mechanical injury.
Data on the ability of butoconazole to penetrate into breast milk are not available. During lactation cream should be used with caution.
Dosing and Administration
Ginofort is a drug intended for intravaginal use. It should be inserted using a special applicator nozzle as deep as possible into the vagina.
The dose of medication, as well as the need to prescribe concomitant treatment, is determined by the attending physician, taking into account the characteristics of the clinical situation.
The standard scheme of Ginofort application involves the single injection of 5 grams of cream (the contents of one applicator). The indicated dose is equivalent to 100 mg of butoconazole nitrate. The procedure can be carried out at any time of the day, however, a more pronounced therapeutic effect can be achieved by administering the cream at bedtime.
Within three days after the introduction of Ginofort should not be irrigated vaginal mucosa and douching. This is due to the fact that the drug is characterized by high bioadhesiveness and, with intravaginal use, remains on the vaginal mucosa for 4-5 days, and douching and irrigation reduce its pharmacological effectiveness.
In situations where the clinical signs of the disease persist even after the application of a vaginal cream, it is necessary to re-examine and pass a smear for bacteriological examination in order to determine the new pathogen or confirm the previous diagnosis.
According to the annotation, Ginofort is usually well tolerated by patients. However, in some cases there are local adverse reactions that are most often expressed as burning sensation, itching and soreness in the vagina. Spastic pain may also appear in the lower abdomen or in the pelvic area.
In patients with hypersensitivity to any of the auxiliary components of Gynofort or butoconazole, local and systemic allergic reactions can develop, including flushing of the skin and mucous membranes, rashes, and urticaria.
When these or other adverse events, Gynoforth treatment is stopped. If the side effects are severe, the vaginal mucosa should be thoroughly washed to remove any cream residue from it.
With intravaginal Ginofort overdose is considered unlikely. If the cream is accidentally swallowed, it is necessary to do a gastric lavage and, if necessary, to carry out symptomatic therapy.
Before starting treatment, it is necessary to establish the diagnosis accurately based on the results of microscopic and / or cultural studies of a smear taken from a woman.
The mineral oil contained in the preparation can reduce the strength of latex and rubber products, and, consequently, the effectiveness of condoms and latex-made diaphragms. For this reason, latex contraception is not recommended for use within 72 hours after administration of Gynofort.
Gynofort's analogs on the mechanism of action: Gainomax, Ginalgin, Ginesol 7, Gyno-travogen, Imidil, Ifenek, Candide, Klomegel, Lomeksin, Metrogil, Metronidazole, Ornion, Trihopol, Funginal, Vagiferon, Metromikon-Neo.
Terms and conditions of storage
Gynofort should be stored at a temperature of 15-25 ° C. The shelf life of the cream is 3 years.